Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProKidney Corp. (PROK : NSDQ)

• Company Description    ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM, N,C. Number of Employees: 231

• Price / Volume Information    Yesterday's Closing Price: $2.01 Daily Weekly Monthly 20 Day Moving Average: 1,179,033 shares Shares Outstanding: 302.32 (millions) Market Capitalization: $607.67 (millions) Beta: 1.70 52 Week High: $3.48 52 Week Low: $1.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.93% 19.47% 12 Week 20.36% 17.80% Year To Date -10.27% -20.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 FRONTIS PLAZA BLVD SUITE 250 - WINSTON-SALEM,NC 27103 USA ph: 336-999-7019 fax: - daniel@lifesciadvisors.com http://www.prokidney.com

• General Corporate Information    Officers Bruce Culleton - Chief Executive Officer and Director Pablo Legorreta - Chairman James Coulston - Chief Financial Officer William F. Doyle - Director Jennifer Fox - Director Peer Information ProKidney Corp. (GSAC) ProKidney Corp. (CASIF) ProKidney Corp. (ALCD.) ProKidney Corp. (OMNN) ProKidney Corp. (CGPI.) ProKidney Corp. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74291D104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 302.32 Most Recent Split Date: (:1) Beta: 1.70 Market Capitalization: $607.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 742.87 EPS Growth vs. Year Ago Period: -15.38% vs. Previous Quarter: -7.14% Sales Growth vs. Year Ago Period: -32.13% vs. Previous Quarter: -33.63% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - -27.39 03/31/26 - -21.39 12/31/25 - -18.83 Current Ratio 06/30/26 - 8.36 03/31/26 - 9.06 12/31/25 - 9.13 Quick Ratio 06/30/26 - 8.36 03/31/26 - 9.06 12/31/25 - 9.13 Operating Margin 06/30/26 - -10,288.39 03/31/26 - -8,131.50 12/31/25 - -7,725.20 Net Margin 06/30/26 - -10,288.39 03/31/26 - -8,131.50 12/31/25 - -7,725.20 Pre-Tax Margin 06/30/26 - -20,388.38 03/31/26 - -17,599.32 12/31/25 - -16,931.47 Book Value 06/30/26 - -2.92 03/31/26 - -3.39 12/31/25 - -3.36 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©